GLP-1 Receptor Agonists for Non-Obese PCOS Patients

Evidence for GLP-1 RAs in PCOS

Current evidence for GLP-1 RAs in PCOS is primarily based on studies in obese patients, with inadequate quality trials resulting in only low to very low certainty evidence 1, 2, 4
Longer-acting GLP-1 RAs (liraglutide and semaglutide) demonstrate more clinical benefits for PCOS compared to shorter-acting options like exenatide 1, 3
Exenatide twice daily did not confer significant benefits over metformin in PCOS patients and was associated with more adverse events 1, 2

Liraglutide has shown superior results for anthropometric outcomes compared to placebo in PCOS patients, but primarily in those with obesity 1, 3
When used with lifestyle interventions, liraglutide helps preserve lean body mass compared to liraglutide alone, suggesting physical activity should accompany treatment 1, 3
Semaglutide appears to be the most potent long-acting GLP-1 RA but has only been studied in one small pilot study in PCOS patients 1, 3

There is a significant research gap regarding GLP-1 RA use specifically in non-obese PCOS patients 3
Current first-line medication treatments for PCOS remain combined oral contraceptives for women not attempting to conceive, not GLP-1 RAs 3

In non-diabetic patients, GLP-1 RAs produce greater weight loss (6.1-17.4%) compared to patients with diabetes (4-6.2%), with semaglutide showing the greatest effects 5, 6

All GLP-1 RAs consistently resulted in greater adverse events than controls, including compared to metformin 2, 3
Common adverse effects include nausea, vomiting, diarrhea, and gastrointestinal reflux 7
Longer-acting GLP-1 RA medications have advantages with improved adherence, glycemic effects, and tolerance compared to shorter-acting options 1, 3

For non-obese PCOS patients, there is insufficient evidence to recommend GLP-1 RAs as first-line therapy 1, 3
If considering GLP-1 RAs in non-obese PCOS patients with metabolic abnormalities, liraglutide or semaglutide would be preferred over exenatide based on available evidence 1, 3
More high-quality, multicenter studies of newer GLP-1 RAs, particularly semaglutide, in non-obese PCOS patients are urgently needed 1, 3
When using GLP-1 RAs in PCOS, combining them with lifestyle interventions including resistance training is recommended to preserve lean body mass 1, 3